Physician profile
David L John
NPI 1568424174
$3,274.74
in general payments reported to CMS, 2019-2025
15 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $24.06 · 2022: $243 · 2023: $205 · 2024: $375 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728 · Travel and Lodging: $946 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.49 |
| Travel and Lodging | $945.64 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.46 | 2022-2025 | |
| Amgen INC. | $836.88 | 2019-2025 | Enbrel, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $220.72 | 2022-2025 | |
| Horizon Therapeutics Plc | $135.47 | 2019 | |
| Janssen Biotech, INC. | $126.53 | 2025 | Tremfya |
| Pfizer INC. | $114.70 | 2022-2025 | |
| Glaxosmithkline, LLC. | $79.41 | 2022 | |
| Ucb, INC. | $53.39 | 2025 | Bimzelx |
| Mallinckrodt Hospital Products INC. | $50.61 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.41 | 2024-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $45.64 | 2023-2024 | Saphnelo |
| Fidia Pharma USA INC. | $25.45 | 2025 | Hymhyn |
| Viiv Healthcare Company | $24.06 | 2020 | |
| Organon LLC | $17.43 | 2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $16.58 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.